Compare CNA & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNA | CYTK |
|---|---|---|
| Founded | 1853 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 10.7B |
| IPO Year | 1994 | 2004 |
| Metric | CNA | CYTK |
|---|---|---|
| Price | $47.36 | $54.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 22 |
| Target Price | N/A | ★ $107.39 |
| AVG Volume (30 Days) | 378.3K | ★ 1.5M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | ★ 33.24 | N/A |
| EPS | ★ 2.67 | N/A |
| Revenue | ★ $14,989,000,000.00 | $13,368,000.00 |
| Revenue This Year | $7.50 | $79.67 |
| Revenue Next Year | N/A | $172.23 |
| P/E Ratio | $17.99 | ★ N/A |
| Revenue Growth | ★ 5.04 | N/A |
| 52 Week Low | $41.53 | $58.43 |
| 52 Week High | $55.71 | $88.31 |
| Indicator | CNA | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 29.20 |
| Support Level | $47.09 | N/A |
| Resistance Level | $49.45 | $66.93 |
| Average True Range (ATR) | 1.04 | 2.39 |
| MACD | -0.06 | -0.35 |
| Stochastic Oscillator | 48.23 | 4.21 |
CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business, and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property, and casualty products to small businesses and medium-scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.